Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGU

Radiomics features of PSMA-based 18F-DCFPyL PET/MRI for prediction of progression in men with high-risk primary prostate cancer undergoing neoadjuvant chemohormonal therapy

Changhee Lee, Petra Lovrec, Tyler Bradshaw, Christos Kyriakopoulos, Wei Huang, David Beebe, David Jarrard, Joshua Lang, Shane Wells and Steve Cho
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 3085;
Changhee Lee
1University of Wisconsin-Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petra Lovrec
1University of Wisconsin-Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tyler Bradshaw
2University of Wisconsin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christos Kyriakopoulos
1University of Wisconsin-Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei Huang
1University of Wisconsin-Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Beebe
1University of Wisconsin-Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Jarrard
1University of Wisconsin-Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua Lang
3University of Wisconsin - Madison, WI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane Wells
1University of Wisconsin-Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Cho
1University of Wisconsin-Madison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

3085

Introduction: Radiomics or computer-extracted imaging features have shown promise at predicting disease progression when applied to PET images. We evaluated the utility of prostate-specific membrane antigen (PSMA)-based 18F-DCFPyL (PyL) PET radiomics features in predicting disease progression in men with high-risk primary prostate cancer (PCa).

Methods: Patients with newly diagnosed high-risk PCa underwent baseline PyL pelvic PET/MRI (PET1) prior to 3 cycles of neoadjuvant chemohormonal therapy with docetaxel and androgen deprivation therapy. PyL pelvic PET/MRI (PET2) was obtained after neoadjuvant chemohormonal therapy and followed by radical prostatectomy. High-risk PCa eligibility was defined as: 1) extracapsular extension (cT3a) or seminal vesicle involvement (cT3b) or invasion of adjacent structures (cT4), serum PSA >20 ng/mL or a Gleason score of 8 to 10 and/or regional lymph node enlargement and 2) oligometastatic disease, defined as disseminated metastases beyond regional lymph nodes by standard-of-care imaging with three or less bone metastases but no visceral metastases. Patients underwent follow-up PyL PET/MRI imaging at one year after prostatectomy, or earlier if they met the criteria of prostate-specific antigen (PSA) progression, and subsequent clinical follow-up. Primary PCa lesions were assessed at both imaging time points (PET1 and PET2). Prostates were contoured based on oblique axial T2W MRI by an experienced genitourinary radiologist and transferred to PET images using MIM Encore software v6.8.7. To assess primary PCa heterogeneity, radiomics features were extracted from PET1 including the shape and size as well as higher-order features using the LIFEx software v7.1.0. To assess primary PCa therapy response, PET standardized updated value (SUV) parameters including SUVmax were assessed at PET1 and PET2. All PET features were correlated with time to PSA progression using univariable Cox regression. Least absolute shrinkage and selection operator (LASSO) regression was used to select key variables for multivariable Cox regression analysis. To determine a baseline false-discovery rate, the statistical analysis was repeated with sham data (i.e., random variables).

Results: Twenty-seven (mean age: 61.2 years, range: 44-71) were enrolled. Fifty-two radiomics features including nine conventional metabolic parameters were extracted and analyzed. Nine patients were disease-free, and 18 patients had PSA progression with a median time to progression of 209 days (range 63-587). Median clinical follow-up was 758 days (range 378-1140). Univariable analysis found 29 radiomics features including SUVmax in PET1 and PET2 to be significant predictors of time to progression. Three features including gray-level zone length matrix (GLZLM)_gray-level non-uniformity (GLNU) of PET1, skewness of PET1, and PET2 SUVmax were selected by the Lasso regression. Multivariable Cox regression analysis found GLZLM_GLNU of PET1 (odds ratio: 1.154, p = 0.005) and SUVmax of PET2 (odds ratio: 1.053, p = 0.017) to be significant predictors of progression (Table 1). In comparison, analysis of sham data found 5 significant variables in univariable regression and 1 significant variable in multivariable regression after LASSO selection. For the multivariable model, pseudo-R2 was 0.61 using real data vs 0.36 using sham data.

Conclusions: Radiomics features of PSMA-based PyL PET1 and SUVmax of PET2 may be useful biomarkers of disease progression in high-risk PCa patients undergoing neoadjuvant chemohormonal therapy. Further studies with larger cohorts are needed to confirm the clinical utility of these parameters.

Funding resources:

DOD PCRP Impact Award PC15053 (UW-Madison)

NIH/NCI 1P41EB024495-01 (JHU) - Service Project 2 (UW-Madison)

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiomics features of PSMA-based 18F-DCFPyL PET/MRI for prediction of progression in men with high-risk primary prostate cancer undergoing neoadjuvant chemohormonal therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radiomics features of PSMA-based 18F-DCFPyL PET/MRI for prediction of progression in men with high-risk primary prostate cancer undergoing neoadjuvant chemohormonal therapy
Changhee Lee, Petra Lovrec, Tyler Bradshaw, Christos Kyriakopoulos, Wei Huang, David Beebe, David Jarrard, Joshua Lang, Shane Wells, Steve Cho
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 3085;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radiomics features of PSMA-based 18F-DCFPyL PET/MRI for prediction of progression in men with high-risk primary prostate cancer undergoing neoadjuvant chemohormonal therapy
Changhee Lee, Petra Lovrec, Tyler Bradshaw, Christos Kyriakopoulos, Wei Huang, David Beebe, David Jarrard, Joshua Lang, Shane Wells, Steve Cho
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 3085;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Comparison of Diagnostic Sensitivity Between [18F]Florastamin and [18F]FDG PET/CT in the Patients with Prostate Cancer
  • Interobserver agreement for [18F]F-PSMA-1007 PET/CT images according to the E-PSMA criteria in prostate cancer patients.
  • Organ-based dosimetry of a novel albumin-binding 177Lu-PSMA agent: interim results of phase 1 clinical trial of Ludotadipep
Show more GU

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire